Literature DB >> 22736751

Natural, innate improvements in multiple sclerosis disability.

Helen Tremlett1, Feng Zhu, John Petkau, Joel Oger, Yinshan Zhao.   

Abstract

BACKGROUND: Improvements in multiple sclerosis (MS) disability have recently been reported in immunomodulatory drug (IMD) clinical trials and observational studies. However, improvements have rarely been examined in natural history or IMD naive patients. We investigated annual and biennial improvements in Expanded Disability Status Scale (EDSS) scores in British Columbia, Canada.
METHODS: The British Columbian MS database was accessed for definite MS patients (1980-2009). Consecutive IMD-free EDSS scores one and two years apart (± 3 months) were examined; improvements (≥0.5,≥1,≥2 EDSS points) and sustained improvements (confirmed at one year) were described. The influence of patient characteristics on improvements was examined using logistic regression.
RESULTS: From 16,132 EDSS scores, 7653 yearly and 5845 biennial EDSS intervals were available for 2961 and 2382 patients respectively. Of the yearly intervals, 14.9% showed an improvement (≥0.5 points), 8.3% ≥1 point and 2.2% ≥2 point improvement, with nearly half being sustained. Corresponding worsenings were observed in 32.9%, 20.5% and 7.9% respectively, with stability in just over half (53%). Biennial findings were similar. Characteristics generally associated with improvements included: female sex, younger age, shorter disease duration, relapsing-onset and presence of moderate disability (compared with mild or advanced) and a previous episode of worsening (disassociated from a relapse). However, improvements were also observed after periods of stability and in primary-progressive MS.
CONCLUSION: Improvements in MS disability over one or two years are not unusual. We suggest the term 'innate improvements'. Our findings have implication for the design of clinical trials and observational studies in MS targeting improvements on the EDSS.

Entities:  

Mesh:

Year:  2012        PMID: 22736751     DOI: 10.1177/1352458512439119

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  9 in total

1.  Disease mechanisms in MS: phases of disease improvement unrelated to relapses.

Authors:  Oluf Andersen
Journal:  Nat Rev Neurol       Date:  2012-09-11       Impact factor: 42.937

2.  Fractional anisotropy of white matter, disability and blood iron parameters in multiple sclerosis.

Authors:  Estelle Herbert; Penelope Engel-Hills; Coenraad Hattingh; Jean-Paul Fouche; Martin Kidd; Christine Lochner; Maritha J Kotze; Susan J van Rensburg
Journal:  Metab Brain Dis       Date:  2018-02-02       Impact factor: 3.584

Review 3.  Pathology-supported genetic testing as a method for disability prevention in multiple sclerosis (MS). Part II. Insights from two MS cases.

Authors:  Susan J van Rensburg; Coenraad Hattingh; Clint Johannes; Kelebogile E Moremi; Armand V Peeters; Carel J van Heerden; Rajiv T Erasmus; Annalise E Zemlin; Merlisa C Kemp; Mariaan Jaftha; Aye Aye Khine; Felix C V Potocnik; Lindiwe Whati; Penelope Engel-Hills; Ronald van Toorn; Maritha J Kotze
Journal:  Metab Brain Dis       Date:  2021-03-12       Impact factor: 3.584

4.  A longitudinal model for disease progression was developed and applied to multiple sclerosis.

Authors:  Michael Lawton; Kate Tilling; Neil Robertson; Helen Tremlett; Feng Zhu; Katharine Harding; Joel Oger; Yoav Ben-Shlomo
Journal:  J Clin Epidemiol       Date:  2015-05-14       Impact factor: 6.437

5.  A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.

Authors:  Vida Hamidi; Elisabeth Couto; Tove Ringerike; Marianne Klemp
Journal:  J Clin Med Res       Date:  2017-12-30

Review 6.  Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2013-09       Impact factor: 11.431

7.  A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity.

Authors:  Gro O Nygaard; Elisabeth G Celius; Sigrid A de Rodez Benavent; Piotr Sowa; Marte W Gustavsen; Anders M Fjell; Nils I Landrø; Kristine B Walhovd; Hanne F Harbo
Journal:  PLoS One       Date:  2015-08-17       Impact factor: 3.240

8.  Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003).

Authors:  Nicolas Collongues; Jens Kuhle; Charidimos Tsagkas; Julien Lamy; Nicolas Meyer; Christian Barro; Katrin Parmar; Michael Amann; Jens Wuerfel; Ludwig Kappos; Thibault Moreau; Jerome de Seze
Journal:  Brain Behav       Date:  2020-12-13       Impact factor: 3.405

9.  Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.

Authors:  Bruce Ac Cree; Jeffrey A Cohen; Anthony T Reder; Davorka Tomic; Diego Silva; Daniela Piani Meier; Annik K Laflamme; Shannon Ritter; David Leppert; Ludwig Kappos
Journal:  Mult Scler       Date:  2021-03-26       Impact factor: 6.312

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.